LPP
MCID: PST062
MIFTS: 46

Pustulosis Palmaris Et Plantaris (LPP)

Categories: Rare diseases, Skin diseases

Aliases & Classifications for Pustulosis Palmaris Et Plantaris

MalaCards integrated aliases for Pustulosis Palmaris Et Plantaris:

Name: Pustulosis Palmaris Et Plantaris 20 58 54 32
Localized Pustular Psoriasis 20 58 70
Palmoplantar Pustulosis 20 58
Ppp 20 58
Lpp 20 58
Generalized Pustular Psoriasis 70
Pustulosis of Palms and Soles 70

Characteristics:

Orphanet epidemiological data:

58
pustulosis palmaris et plantaris
Inheritance: Autosomal dominant,Autosomal recessive;

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

ICD10 32 L40.3
ICD10 via Orphanet 33 L40.3
UMLS via Orphanet 71 C0030246
Orphanet 58 ORPHA163927
UMLS 70 C0030246 C0263365 C0343055

Summaries for Pustulosis Palmaris Et Plantaris

GARD : 20 Pustulosis palmaris et plantaris (PPP) is a rare and chronic inflammatory condition that primarily affects the palms of the hands and soles of the feet. Signs and symptoms of the condition generally develop during adulthood and include crops of pustules on one or both hands and/or feet that erupt repeatedly over time. Affected individuals may also experience itching (pruritus), pain, or a burning sensation. The classification of PPP is controversial. Some have proposed that PPP is a variant of psoriasis, while others believe it to be a separate disease. Though the area of involvement is often limited, PPP can have a significant effect on quality of life and can interfere with walking or other daily activities. PPP often has a chronic and relapsing course and may be resistant to treatment. Treatment options may include topical steroids, emollients, certain medications called retinoids, and treatment with light (phototherapy).

MalaCards based summary : Pustulosis Palmaris Et Plantaris, also known as localized pustular psoriasis, is related to spondyloarthropathy 1 and pustulosis of palm and sole. An important gene associated with Pustulosis Palmaris Et Plantaris is AP1S3 (Adaptor Related Protein Complex 1 Subunit Sigma 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ixekizumab and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include tonsil and t cells, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Wikipedia : 73 Pustulosis palmaris et plantaris is a chronic recurrent pustular dermatosis (that is, a pustulosis or... more...

Related Diseases for Pustulosis Palmaris Et Plantaris

Diseases related to Pustulosis Palmaris Et Plantaris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 30.7 TNF CD40LG CCR6
2 pustulosis of palm and sole 30.7 TNF IL36RN CCR6 AP1S3
3 chlamydia 30.3 TNF IL5 CD79A
4 nasopharyngitis 30.3 TNF IL5 CCR6
5 glomerulonephritis 30.2 TGFB1 ITGAL ELANE CD79A CD40LG
6 synovitis 30.1 TNF SELE ITGB1
7 mycosis fungoides 30.1 ITGAL IL5 CXCR3 CCR6 CCR4
8 cutaneous t cell lymphoma 30.1 IL5 CXCR3 CCR6 CCR4
9 allergic disease 30.1 TNF IL5 CXCR3 CCR6
10 fungal infectious disease 30.0 TNF IL5 CCR6
11 iga glomerulonephritis 30.0 TGFB1 SELE CD79A CD40LG CCR6
12 pustular psoriasis 30.0 TNF IL36RN ELANE AP1S3
13 pyoderma gangrenosum 30.0 TNF ITGB2 CCR6
14 primary biliary cholangitis 30.0 ITGAL CD79A CD40LG CCR6
15 arthritis 29.9 TNF TGFB1 ITGB2 ITGAL CCR6 CCL20
16 lichen planus 29.9 TNF ITGAL CXCR3
17 dermatitis 29.9 TNF IL5 CXCR3 CCR6 CCR4
18 spondylarthropathy 29.9 TNF ITGAL
19 proteasome-associated autoinflammatory syndrome 1 29.9 TNF SELE IL5 ELANE
20 impetigo 29.9 IL36RN ELANE CCR6
21 celiac disease 1 29.9 TNF IL5 CXCR3 CD79A CCR6
22 psoriasis 14, pustular 29.8 TNF IL36RN AP1S3
23 vasculitis 29.7 TNF SELE ITGB2 ELANE CD79A CD40LG
24 pyoderma 29.6 TNF ITGB2 IL36RN CCR6
25 dermatitis, atopic 29.6 TNF SELE IL5 CXCR3 CCR6 CCR4
26 inguinal hernia 29.5 SELE ITGB1 ELANE
27 spondyloarthropathy 29.5 TNF SELE ITGAL
28 human immunodeficiency virus infectious disease 29.4 TNF ITGAL CXCR3 CD79A CCR6
29 contact dermatitis 29.3 TNF SELE IL5 CXCR3 CCR6 CCR4
30 autoimmune disease 29.0 TNF TGFB1 ITGAL IL5 CXCR3 CD79A
31 rheumatoid arthritis 28.7 TNF TGFB1 SELE ITGB2 ITGAL ELANE
32 thrombocytopenia 28.3 TNF TGFB1 SELE ITGB2 ITGAL CXCR3
33 skin disease 28.3 TNF SELE ITGB2 ITGB1 ITGAL IL5
34 psoriasis 28.2 TNF SELE ITGB2 ITGB1 ITGAL IL5
35 inflammatory bowel disease 27.4 TNF TGFB1 SMAD7 SELE ITGB2 ITGAL
36 periodontitis, aggressive, 1 11.4
37 lichen planus pigmentosus 11.2
38 lichen planus pemphigoides 11.2
39 psoriasis 1 11.1
40 frontal fibrosing alopecia 11.1
41 lipomatosis, multiple 11.1
42 transaldolase deficiency 11.1
43 vacterl association 11.0
44 tetralogy of fallot 11.0
45 esophageal atresia 11.0
46 schizophrenia 11.0
47 pseudopelade of brocq 10.9
48 pneumonic plague 10.9
49 plague 10.9
50 leukemia, acute myeloid 10.9

Graphical network of the top 20 diseases related to Pustulosis Palmaris Et Plantaris:



Diseases related to Pustulosis Palmaris Et Plantaris

Symptoms & Phenotypes for Pustulosis Palmaris Et Plantaris

GenomeRNAi Phenotypes related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCL20 CCR6 CD79A IL5 ITGAL SELE

MGI Mouse Phenotypes related to Pustulosis Palmaris Et Plantaris:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CCR4 CCR6 CD40LG CD79A CXCR3 ELANE
2 homeostasis/metabolism MP:0005376 10.27 CCL20 CCR6 CD40LG CD79A CXCR3 ELANE
3 immune system MP:0005387 10.22 CCR4 CCR6 CD40LG CD79A CXCR3 ELANE
4 cellular MP:0005384 10.17 CD40LG CD79A CXCR3 ITGAL ITGB1 ITGB2
5 integument MP:0010771 9.96 CD40LG ELANE IL36RN ITGB1 ITGB2 SELE
6 neoplasm MP:0002006 9.76 CD79A CXCR3 ELANE IL5 ITGAL ITGB1
7 normal MP:0002873 9.61 CCR6 CD79A CXCR3 ELANE IL36RN ITGB1
8 respiratory system MP:0005388 9.17 CCR4 CXCR3 IL5 ITGB1 SELE TGFB1

Drugs & Therapeutics for Pustulosis Palmaris Et Plantaris

Drugs for Pustulosis Palmaris Et Plantaris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
2 Dermatologic Agents Phase 4
3
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
4
tannic acid Approved Phase 3 1401-55-4
5
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
6
Brodalumab Approved, Investigational Phase 3 1174395-19-7
7 Antibodies Phase 3
8 Immunoglobulins Phase 3
9 Antibodies, Monoclonal Phase 3
10 Immunologic Factors Phase 3
11
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
12 Vaccines Phase 2
13 Antirheumatic Agents Phase 2
14 Anti-Inflammatory Agents Phase 2
15 Pharmaceutical Solutions Phase 2
16 Analgesics, Non-Narcotic Phase 2
17 Analgesics Phase 2
18 Anti-Inflammatory Agents, Non-Steroidal Phase 2
19
Sargramostim Approved, Investigational Phase 1 123774-72-1, 83869-56-1
20
Lenograstim Approved, Investigational Phase 1 135968-09-1
21
Molgramostim Investigational Phase 1 99283-10-0
22 Adjuvants, Immunologic Phase 1

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
2 A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis Completed NCT01952015 Phase 3
3 A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis Completed NCT02533375 Phase 3 Adalimumab
4 A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed NCT03022045 Phase 3 risankizumab
5 A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed NCT02343744 Phase 3 Guselkumab
6 A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis Completed NCT02641730 Phase 3 Guselkumab;Placebo
7 A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks Completed NCT02008890 Phase 3
8 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult Japanese Subjects With Moderate to Severe Palmoplantar Pustulosis Recruiting NCT04451720 Phase 3 Risankizumab;Placebo
9 A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis Recruiting NCT04061252 Phase 3 KHK4827;Placebo
10 A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis Completed NCT03619902 Phase 2 ANB019
11 Effisayil™ 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of BI 655130 in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity. Completed NCT03782792 Phase 2 Spesolimab;Placebo
12 A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis Completed NCT03988335 Phase 2 RIST4721;Placebo
13 A Multicenter, Open Label, Single-arm Pilot Study to Evaluate the Efficacy and Safety of Oral Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Completed NCT04572997 Phase 2 Apremilast
14 Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP) Completed NCT03135548 Phase 2 Spesolimab (low dose);Placebo;Spesolimab (high dose)
15 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis Completed NCT01845987 Phase 2 Placebo;CNTO 1959
16 Effisayil™ 2: Multi-center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients With History of GPP Recruiting NCT04399837 Phase 2 Spesolimab;Placebo
17 An Open-label, Long Term Extension Study to Assess the Safety and Efficacy of BI 655130 Treatment in Patients With Generalized Pustular Psoriasis (GPP) Recruiting NCT03886246 Phase 2 Spesolimab;Spesolimab
18 An Open-label, Long Term Safety Trial of Spesolimab Treatment in Patients With Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials Recruiting NCT04493424 Phase 2 Spesolimab
19 A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis Active, not recruiting NCT03633396 Phase 2 Placebo
20 Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) Active, not recruiting NCT04015518 Phase 2 Spesolimab;Placebo
21 A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Palmoplantar Pustulosis in Japan Active, not recruiting NCT04057937 Phase 2 Apremilast;Placebo
22 Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis Terminated NCT01197989 Phase 2
23 Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis. Completed NCT02978690 Phase 1 BI655130
24 A Multicenter, Open-label, 2-regimen, Repeat-dose Study to Assess the Safety and Pharmacokinetics of Intravenous CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Recruiting NCT03972280 Phase 1
25 The Immune Signature of Palmoplantar Pustulosis Completed NCT01780857
26 Registry of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan Recruiting NCT04459507
27 Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence Active, not recruiting NCT04566471

Search NIH Clinical Center for Pustulosis Palmaris Et Plantaris

Genetic Tests for Pustulosis Palmaris Et Plantaris

Anatomical Context for Pustulosis Palmaris Et Plantaris

MalaCards organs/tissues related to Pustulosis Palmaris Et Plantaris:

40
Tonsil, T Cells

Publications for Pustulosis Palmaris Et Plantaris

Articles related to Pustulosis Palmaris Et Plantaris:

(show top 50) (show all 196)
# Title Authors PMID Year
1
What do we know about palmoplantar pustulosis? 20
27521275 2017
2
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. 20
27113059 2016
3
Levels of proelafin peptides in the sera of the patients with generalized pustular psoriasis and pustulosis palmoplantaris. 54 61
10877128 2000
4
Soluble E-selectin as a marker of disease activity in pustulosis palmaris et plantaris. 54 61
10598762 1999
5
Medullasin levels in neutrophils of patients with pustulosis palmaris et plantaris. 54 61
8315109 1993
6
Similarity and difference between palmoplantar pustulosis and pustular psoriasis. 61
33650702 2021
7
Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma. 61
33404105 2021
8
Guselkumab for the treatment of palmoplantar pustulosis. 61
32321322 2020
9
Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. 61
32201085 2020
10
Lack of association between mutation in IL36RN and palmoplantar pustular psoriasis in Chinese patients. 61
31789248 2019
11
Interleukin (IL)-8 and IL-36γ but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis. 61
29896852 2019
12
Treatment outcome and prognostic factors of tonsillectomy for palmoplantar pustulosis and pustulotic arthro-osteitis: A retrospective subjective and objective quantitative analysis of 138 patients. 61
29732605 2018
13
Identification of nail features associated with psoriasis severity. 61
27599783 2017
14
Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic? 61
28223746 2017
15
Cefcapene Pivoxil Hydrochloride Is a Potentially New Treatment for Palmoplantar Pustulosis with Pustulotic Arthro-Osteitis. 61
26440444 2015
16
Pustulosis palmaris et plantaris successfully treated with leukotriene antagonist. 61
25672791 2014
17
Caveolin-1 expression in different types of psoriatic lesions: analysis of 66 cases. 61
24891649 2014
18
Vesicular LL-37 contributes to inflammation of the lesional skin of palmoplantar pustulosis. 61
25330301 2014
19
Presence of keratin-specific antibody-forming cells in palatine tonsils of patients with pustulosis palmaris et plantaris (PPP) and its correlation with prognosis after tonsillectomy. 61
24138121 2014
20
Pustulosis palmaris et plantaris. 61
23709543 2013
21
Cutaneous small vessel vasculitis accompanied by pustulosis palmaris et plantaris. 61
22548039 2012
22
Improvement of pustulosis palmaris et plantaris by periodontal infection control in a patient with chronic periodontitis. 61
22582507 2012
23
Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. 61
21951304 2011
24
Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. 61
21732985 2011
25
Increased peripheral Th17 in patients with pustulosis palmaris et plantaris. 61
21229362 2011
26
Tonsil-related skin diseases and possible involvement of T cell co-stimulation in chronic focal infection. 61
21865697 2011
27
Up-regulation of ß1 integrin on tonsillar T cells and its induction by in vitro stimulation with α-streptococci in patients with pustulosis Palmaris et Plantaris. 61
20714794 2010
28
Unusual case of pemphigus vulgaris mimicking localized pustular psoriasis of the hands and feet. 61
21049731 2010
29
Acrosyringium is the main site of the vesicle/pustule formation in palmoplantar pustulosis. 61
20393482 2010
30
Analysis of psoriatic patients registered in Asahikawa Medical College Hospital from 1983 to 2007. 61
19958446 2009
31
Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis palmaris et plantaris. 61
19268507 2009
32
Up-regulation of CC chemokine receptor 6 on tonsillar T cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris. 61
19659772 2009
33
Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study. 61
19222520 2009
34
Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? 61
18850415 2009
35
Assessment of allergic hypersensitivity to dental materials. 61
19458446 2009
36
Possible involvement of T cell co-stimulation in pustulosis palmaris et plantaris via the induction of inducible co-stimulator in chronic focal infections. 61
18308514 2008
37
[What's new in medicine in 2007?]. 61
18675138 2007
38
Pustulosis palmaris et plantaris with prominent hyperkeratosis of the soles. 61
17169098 2006
39
Regression of pustulosis palmaris et plantaris by periodontal treatment in a subject with severe periodontitis. 61
17184243 2006
40
[Maximilian Koenigsbeck and localized pustular psoriasis]. 61
16799814 2006
41
[A case report of a metal allergy patient whose prosthesis was identified allergenic by non-destructive metal element analysis and a dermatological patch test]. 61
16790970 2006
42
Expression of cutaneous lymphocyte-associated antigen (CLA) in tonsillar T-cells and its induction by in vitro stimulation with alpha-streptococci in patients with pustulosis palmaris et plantaris (PPP). 61
15925831 2005
43
Increase of activated T-cells and up-regulation of Smad7 without elevation of TGF-beta expression in tonsils from patients with pustulosis palmaris et plantaris. 61
15885643 2005
44
Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. 61
16205070 2005
45
Effect of tonsillectomy in patients with pustulosis palmaris et plantaris. 61
15513559 2004
46
Implication of responses to bacterial heat shock proteins, chronic microbial infections, and dental metal allergy in patients with pustulosis palmaris et plantaris. 61
14694830 2003
47
The role of mercury in pustulosis palmaris et plantaris. 61
12762071 2003
48
A case of pustulosis palmaris et plantaris that began as generalized pustular eruption. 61
12692382 2003
49
A survey of psoriasis patients in Japan from 1982 to 2001. 61
12615365 2003
50
New aspects of metal allergy. 61
12588671 2002

Variations for Pustulosis Palmaris Et Plantaris

Expression for Pustulosis Palmaris Et Plantaris

Search GEO for disease gene expression data for Pustulosis Palmaris Et Plantaris.

Pathways for Pustulosis Palmaris Et Plantaris

Pathways related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
2
Show member pathways
13.67 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
3
Show member pathways
13.62 TNF TGFB1 IL5 IL36RN CXCR3 CD40LG
4
Show member pathways
13.49 TNF TGFB1 SMAD7 ITGB2 ITGB1 ITGAL
5
Show member pathways
13.35 TGFB1 ITGB2 ITGB1 ITGAL CXCR3 CCR6
6
Show member pathways
13.31 TNF TGFB1 ITGB2 ITGB1 IL5 CD40LG
7
Show member pathways
13.25 TGFB1 SELPLG SELE ITGB2 ITGB1 ITGAL
8
Show member pathways
13.21 TNF TGFB1 IL5 CXCR3 CD40LG CCR6
9
Show member pathways
13.04 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
10
Show member pathways
12.88 TNF TGFB1 ITGB2 ITGB1 ITGAL
11
Show member pathways
12.77 TNF TGFB1 ITGB2 ITGAL IL5 CD40LG
12
Show member pathways
12.69 TGFB1 ITGB2 ITGB1 ITGAL ELANE
13 12.3 TNF TGFB1 ITGB2 ITGAL
14
Show member pathways
12.26 TNF CXCR3 CCR6 CCR4 CCL20
15
Show member pathways
12.17 TNF TGFB1 ITGB2 ITGB1 CD40LG
16
Show member pathways
12.1 TGFB1 SELPLG SELE ITGB2 ITGB1 ITGAL
17 12.03 ITGB2 ITGB1 ITGAL CD40LG
18 11.95 TNF ITGAL IL5 CD79A
19 11.93 TNF TGFB1 ITGB2 ITGB1
20 11.91 SELPLG SELE ITGB2 ITGB1 ITGAL CD40LG
21 11.87 TNF TGFB1 ITGB2
22 11.86 TNF TGFB1 SELE
23 11.84 SELPLG ITGB2 ITGAL
24 11.83 TGFB1 ITGB1 CD79A
25 11.82 TNF TGFB1 SMAD7
26 11.77 ITGB2 ITGB1 ITGAL
27 11.77 TNF TGFB1 ITGB2 ITGAL CCL20
28 11.72 TNF ITGB2 ITGB1
29
Show member pathways
11.72 TNF IL5 CD40LG
30 11.71 TNF IL5 CXCR3 CCR6
31
Show member pathways
11.63 TNF SELE CD40LG
32 11.58 TNF TGFB1 SMAD7
33 11.58 TNF TGFB1 SMAD7 IL5
34
Show member pathways
11.44 ITGB2 ITGB1 ITGAL
35 11.44 ITGB2 ITGB1 ITGAL
36 11.42 TNF SELPLG ITGB2 ELANE
37 11.38 SELE ITGB1 ELANE
38 11.3 ITGB2 ITGAL CXCR3
39 11.21 TNF TGFB1 IL5
40 11.13 TNF TGFB1 SELE ITGB2 ITGAL CD40LG
41 11.04 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
42 10.83 TNF TGFB1
43 10.83 TNF TGFB1 ITGB2 ITGB1 ITGAL IL5
44 10.75 TGFB1 IL5

GO Terms for Pustulosis Palmaris Et Plantaris

Cellular components related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 TNF TGFB1 SMAD7 SELPLG SELE ITGB2
2 extracellular space GO:0005615 10.01 TNF TGFB1 SELE IL5 IL36RN ELANE
3 integral component of plasma membrane GO:0005887 9.98 TNF SELPLG SELE CXCR3 CD40LG CCR6
4 membrane raft GO:0045121 9.55 TNF SELE ITGB2 ITGB1 CD79A
5 integrin complex GO:0008305 9.5 ITGB2 ITGB1 ITGAL
6 external side of plasma membrane GO:0009897 9.5 TNF ITGB2 CXCR3 CD79A CD40LG CCR6
7 cell surface GO:0009986 9.28 TNF TGFB1 ITGB2 ITGB1 ITGAL ELANE
8 integrin alphaL-beta2 complex GO:0034687 9.26 ITGB2 ITGAL

Biological processes related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 ITGAL IL5 IL36RN CXCR3 CD40LG CCR6
2 cell adhesion GO:0007155 10.02 SELPLG SELE ITGB2 ITGB1 ITGAL CXCR3
3 extracellular matrix organization GO:0030198 9.93 TNF ITGB2 ITGB1 ITGAL
4 immune response GO:0006955 9.92 TNF IL5 IL36RN CXCR3 CD40LG CCR6
5 cytokine-mediated signaling pathway GO:0019221 9.91 TNF TGFB1 ITGB2 ITGB1 IL5 IL36RN
6 regulation of immune response GO:0050776 9.89 ITGB2 ITGB1 ITGAL CD40LG
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.86 TNF TGFB1 ITGB2 CD40LG
8 chemotaxis GO:0006935 9.84 CXCR3 CCR6 CCR4 CCL20
9 cell-matrix adhesion GO:0007160 9.83 ITGB2 ITGB1 ITGAL
10 integrin-mediated signaling pathway GO:0007229 9.81 ITGB2 ITGB1 ITGAL CD40LG
11 B cell differentiation GO:0030183 9.8 ITGB1 CD79A CD40LG
12 cell chemotaxis GO:0060326 9.8 CXCR3 CCR6 CCR4 CCL20
13 calcium-mediated signaling GO:0019722 9.78 SELE CXCR3 CCR6 CCR4
14 positive regulation of MAP kinase activity GO:0043406 9.76 TNF TGFB1 ELANE
15 phagocytosis GO:0006909 9.76 ITGB2 ITGB1 ITGAL ELANE
16 chemokine-mediated signaling pathway GO:0070098 9.73 CXCR3 CCR6 CCR4 CCL20
17 leukocyte tethering or rolling GO:0050901 9.71 TNF SELPLG SELE ITGB1
18 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.66 TNF ITGB2
19 positive regulation of fibroblast migration GO:0010763 9.66 TGFB1 ITGB1
20 pathway-restricted SMAD protein phosphorylation GO:0060389 9.65 TGFB1 SMAD7
21 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.64 TNF TGFB1
22 positive regulation of podosome assembly GO:0071803 9.64 TNF IL5
23 CD40 signaling pathway GO:0023035 9.62 ITGB1 CD40LG
24 regulation of immunoglobulin production GO:0002637 9.62 TNF CD40LG
25 positive regulation of leukocyte tethering or rolling GO:1903238 9.61 SELE ELANE
26 T cell migration GO:0072678 9.61 CCR6 CCL20
27 response to laminar fluid shear stress GO:0034616 9.6 TGFB1 SMAD7
28 positive regulation of mononuclear cell migration GO:0071677 9.58 TNF TGFB1
29 cellular extravasation GO:0045123 9.57 TNF ITGB2
30 leukocyte migration involved in inflammatory response GO:0002523 9.56 SELE ITGB2 ELANE CCR6
31 leukocyte migration GO:0050900 9.56 TNF TGFB1 SELPLG SELE ITGB2 ITGB1
32 leukocyte cell-cell adhesion GO:0007159 9.55 SELE ITGB2 ITGB1 ITGAL CD40LG
33 thymocyte migration GO:0072679 9.52 CCR6 CCL20
34 inflammatory response GO:0006954 9.36 TNF TGFB1 SELE ITGB2 ITGAL IL5

Molecular functions related to Pustulosis Palmaris Et Plantaris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TNF TGFB1 SMAD7 SELPLG SELE ITGB2
2 signaling receptor activity GO:0038023 9.73 ITGB2 ITGB1 CXCR3 CCR6
3 protease binding GO:0002020 9.65 TNF ITGB1 ELANE
4 cell adhesion molecule binding GO:0050839 9.58 ITGB2 ITGB1 ITGAL
5 type I transforming growth factor beta receptor binding GO:0034713 9.46 TGFB1 SMAD7
6 C-C chemokine binding GO:0019957 9.43 CXCR3 CCR6 CCR4
7 C-C chemokine receptor activity GO:0016493 9.33 CXCR3 CCR6 CCR4
8 ICAM-3 receptor activity GO:0030369 9.32 ITGB2 ITGAL
9 chemokine receptor activity GO:0004950 9.13 CXCR3 CCR6 CCR4
10 cytokine activity GO:0005125 9.1 TNF TGFB1 IL5 IL36RN CD40LG CCL20

Sources for Pustulosis Palmaris Et Plantaris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....